13 results about "Endothelial nitric oxide synthase" patented technology

This utility model relates to an innovation of a carotid artery vasodilator that can be used at home and in the emergency room as a supplement to drug treatment for conditions such as carotid artery obstruction in the neck region. It increases the production of nitric oxide mediated by endothelial nitric oxide synthase in the intact endothelial layer of the carotid artery, which is located on the inner surface of the neck brace. It can be applied for a certain period of time for each patient. The intermittent or continuous operation function can be selected through an adjustable power circuit. It only affects the lesion area and does not affect the patient's peripheral blood vessels. It can be used in situations where nitrates may be prohibited. It prevents the reduction of blood flow to the brain tissue that may occur due to jugular venous constriction. The flexible structure of the applicator neck brace (9) can be maintained in the application area for a long time and includes a pulsed magnetic field (PMF).

The invention discloses application of polyol nitrate in frostbite resistance, and belongs to the technical field of skin protection articles. The polyol nitrate is used as an active component of the ointment, and by slowly releasing nitric oxide and activating vascular endothelial nitric oxide synthase, spasm capillaries in the early stage of frostbite are effectively relaxed, platelet aggregation and thrombosis are inhibited, so that the pathological cascade reaction of frostbite is blocked, and the prevention and treatment effects on frostbite are remarkably improved. Compared with the prior art, the polyol nitrate and the ointment are scientific and reasonable in preparation method and safe and convenient to use, and a brand-new and effective solution is provided for prevention and treatment of skin frostbite in a cold environment.

A carotid vasodilator device for use in the treatment of conditions such as carotid artery occlusion in the neck, comprising: - a coil that enables the generation of a pulsed magnetic field, - a control unit (1) which enables the control of magnetic field signals and the adjustment of the pulsed magnetic field parameters applied to the neck area, - a cervical collar (9) providing endothelial nitric oxide synthase-mediated nitric oxide synthesis in the intact endothelial layer of the carotid artery on the inner surface of the neck by applying a regional pulsed magnetic field.

Nucleic acid molecules comprising truncated forms of the human cytomegalovirus (CMV) promoter are operably linked to a transgene of interest, including those encoding eNOS protein are taught. Vectors comprising these nucleic acid molecules and host cells transformed by these vectors and methods of producing cellular compositions are used for the treatment of a variety of pulmonary and cardiac diseases. There is provided a truncated human cytomegalovirus (CMV) enhancer element comprising SEQ ID NO: 1 or a functional derivative thereof. A truncated human cytomegalovirus (CMV) promoter comprising the truncated CMV enhancer element is taught. A polynucleotide expression cassette comprising the truncated CMV promoter and a transcribable polynucleotide operably linked to the truncated CMV promoter polynucleotide construct, a host cell comprising the polynucleotide expression cassette, and use of the host cell treat renal, vascular, pulmonary, or cardiac disease in the patient are taught.

The application discloses a kind of micro bone-blood vessel symbiosis based on gene activation and its preparation method and application.The system includes: the amorphous calcium phosphate nanoparticles of L-arginine, bovine serum albumin and alendronate sodium co-modified loaded BMP-2 mRNA;Methacrylic acid gel hydrogel microspheres encapsulating the nanoparticle;And E7 peptide grafted on the surface of hydrogel microspheres.It is captured by E7 peptide bone marrow mesenchymal stem cells, and delivers BMP-2 mRNA to activate intracellular BMP-2 and endothelial-type nitric oxide synthase expression, while using L-arginine to drive in-situ synthesis of nitric oxide, to synergistically enhance stem cell osteogenic differentiation and promote vascular sprouting ability, realize the vascularization synchronous regeneration of bone defect.The system solves the problem of unstable exogenous nitric oxide donor and bone-vessel regeneration decoupling, and has excellent biocompatibility and bone repair efficiency.

A nutritional supplement includes one or more immune modulators that support a subject's cellular immunity, as well as ingredients that enhance the production and use of nitric oxide by the subject's body to better regulate the subject's cellular immunity. Such a nutritional supplement may include nano-fraction immune modulators, transfer factor, or plant transfer factor, as well as sufficient amounts of vitamin B9 and vitamin B12 to increase endothelial nitric oxide synthetase activity in a body of a subject. Methods for increasing endothelial nitric oxide synthetase activity in the body of a subject are also disclosed.

A method for the in vitro diagnosis of the risk of delayed cerebral ischemia (DCI) following subarachnoid hemorrhage from a ruptured aneurysm (aSAH) which includes the following steps: collection of a blood sample from the patient; quantitative determination of 8-iso-prostaglandin F2α (F2-IsoP) concentration in plasma; comparison of the concentration thereof in plasma with the reference value; collection of at least one further blood sample; quantitative determination of the concentration of endothelial nitric oxide synthase (eNOS) and / or nicotinamide adenine dinucleotide phosphate (NADPH) in plasma; comparison of the concentration thereof in plasma with the reference value; analysis of the obtained results and establishing diagnosis. A marker substance for the in vitro diagnosis of the risk of occurrence of DCI selected from 8-iso-prostaglandin F2α (F2-IsoP), endothelial nitric oxide synthase (eNOS), nicotinamide adenine dinucleotide phosphate (NADPH) and combinations thereof and the use thereof as a screening test for the in vitro diagnosis of DCI following aSAH.

The application discloses a magnesium alloy vascular stent material with a nitric oxide in-situ catalytic release coating and a preparation method thereof, and is mainly used for solving the problems of excessive hyperplasia and delayed endothelialization of the current magnesium alloy vascular stent. The lipoic acid-arginine coating with the in-situ catalytic release ability of nitric oxide is constructed on the surface of the pretreated magnesium alloy vascular stent material. The lipoic acid-arginine coating is closely adhered to the surface of the pretreated magnesium alloy stent based on the hydrogen bond effect. The fixed arginine in the coating serves as fuel for synthesizing nitric oxide. The endothelial cells generate nitric oxide in-situ through endothelial nitric oxide synthase. The lipoic acid serves as an endothelial nitric oxide synthase enhancer, increases the level of the endothelial nitric oxide synthase in the endothelial cells, and decomposes arginine into nitric oxide, so that the sufficient supply of in-situ nitric oxide is ensured. The coating significantly delays the degradation rate of the magnesium alloy stent, promotes the reconstruction of the natural endothelium, and prevents restenosis.

The invention discloses application of a kappa-opioid receptor stimulant U50488H in preparation of a medicine for improving radioactive aortic vascular endothelial injury, and belongs to the technical field of biological medicine. By selecting the kappa-opioid receptor stimulant with the (-)-U50488H isomer structure, the radioactive aortic vascular endothelial injury can be effectively improved. A plurality of experiments prove that the kappa-opioid receptor stimulant medicine containing the (-)-U50488H isomer structure is a medicine for slowing down aortic endothelial cell proliferation, inhibiting oxidative stress injury, improving protein level expression of Nrf2 / HO-1, improving nitric oxide level, improving endothelial nitric oxide synthase activity and reducing inflammatory response; when radioactive vascular endothelium is damaged, an Nrf2 / HO-1 path can be enhanced by activating a kappa-opioid receptor stimulant U50488H, so that the anti-oxidation and anti-inflammatory effects are achieved, and the vascular endothelium function of the kappa-opioid receptor stimulant U50488H is finally improved.

The utility model relates to a low -cost magnetic erection device, and the device promotes the production of nitric oxide through endothelial nitric oxide synthase (eNOS) from endothelium, that is, the innermost layer of blood vessel structure, does not need contact and does not contain chemical substances when applying in vitro, increases the blood circulation of the tissue of application area, simultaneously provides the possibility of repeated use and portable use through its in vitro, promotes the blood vessel expansion of application area through pulsed electromagnetic field (PEMF), increases the synthesis of tissue growth factor (such as vascular endothelial growth factor), does not cause painful irritation, and can adjust power, frequency and duration.

A magnetic erection aid device which, through the action of a pulsed magnetic field or radiofrequency field, increases nitric oxide production and tissue blood flow in the applied area via endothelial nitric oxide synthase from the endothelial layer, namely the innermost layer of the vascular structure, characterized in that it comprises the following: - at least one coil generating a pulsed magnetic field effect, - at least one high-frequency circuit (3) generating a high-frequency electromagnetic field effect, - an applicator pad (4) which increases the production of nitric oxide from the endothelial layer, namely the innermost layer of the vascular structure, by endothelial nitric oxide synthase and ensures its homogeneous distribution, whereby the electromagnetic effect occurs without contact with the application area, and - a control unit (9) which makes it possible to adjust the power of the high-frequency field and the generated pulsed magnetic field effect or the operating time or frequency of the device, and makes it possible to apply the pulsed magnetic field effect or the high-frequency electromagnetic field effect in combination or separately.

A method for the in vitro diagnosis of the risk of delayed cerebral ischemia (DCI) following subarachnoid hemorrhage from a ruptured aneurysm (aSAH) which includes the following steps: collection of a blood sample from the patient; quantitative determination of 8-iso-prostaglandin F2α (F2-IsoP) concentration in plasma; comparison of the concentration thereof in plasma with the reference value; collection of at least one further blood sample; quantitative determination of the concentration of endothelial nitric oxide synthase (eNOS) and / or nicotinamide adenine dinucleotide phosphate (NADPH) in plasma; comparison of the concentration thereof in plasma with the reference value; analysis of the obtained results and establishing diagnosis. A marker substance for the in vitro diagnosis of the risk of occurrence of DCI selected from 8-iso-prostaglandin F2α (F2-IsoP), endothelial nitric oxide synthase (eNOS), nicotinamide adenine dinucleotide phosphate (NADPH) and combinations thereof and the use thereof as a screening test for the in vitro diagnosis of DCI following aSAH.

This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally. The intermediate phase may be while the patient's breathing is being assisted mechanically.